HIV感染者接种13价肺炎球菌结合疫苗后接种23价多糖疫苗的血清学无应答预测因素
研究纳入52名接受抗逆转录病毒治疗且未接种过肺炎球菌疫苗的HIV感染者,先接种PCV13,60天后接种PPV23,30天后评估12种血清型的抗体应答。46%(95%CI 32-61,n=24)达到血清保护。接种前GMC低于100 ng/ml者无应答风险升高(调整OR 8.7,95%CI 1.2-63.6,p=0.0438)。
要点
- 52名HIV感染者完成PCV13后60天接种PPV23,46%(95%CI 32-61,n=24)达到血清保护。
- 血清型14、18C和19F的GMC最高,血清型3、4和6B的GMC最低。
- 接种前GMC低于100 ng/ml与无应答风险升高相关(调整OR 8.7,95%CI 1.2-63.6,p=0.0438)。
核心结论
- 研究人群中不足一半在PCV13和PPV23免疫后达到抗肺炎球菌血清保护水平。
- 接种前低GMC水平与无应答相关。
- 需要进一步研究以优化疫苗接种策略,使该高危人群获得更高的血清保护。
研究设计与样本
- 研究纳入52名接受抗逆转录病毒治疗且既往未接种肺炎球菌疫苗的HIV感染者。
- 先接种13价肺炎球菌结合疫苗(PCV13),60天后接种23价肺炎球菌多糖疫苗(PPV23)。
- 接种PPV23后30天评估针对PCV13和PPV23共同覆盖的12种血清型的抗体应答。
- 血清保护定义为所有血清型几何平均浓度(GMC)较基线升高≥2倍且水平高于1.3 µg/ml。
- 采用逻辑回归评估与无应答的关联。
主要发现
- 52名病毒学抑制的HIV感染者中位年龄50岁(IQR 44-55),中位CD4计数634 cells/mm3(IQR 507-792)。
- 46%(95%CI 32-61,n=24)达到血清保护。
- 血清型14、18C和19F的GMC最高,血清型3、4和6B的GMC最低。
- 接种前GMC低于100 ng/ml者与高于100 ng/ml者相比,无应答的调整OR为8.7(95%CI 1.2-63.6,p=0.0438)。
关键数值与推荐
- 血清保护定义为所有血清型GMC较基线升高≥2倍且水平高于1.3 µg/ml。
- 接种前GMC低于100 ng/ml与无应答风险升高相关(调整OR 8.7,95%CI 1.2-63.6,p=0.0438)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究以优化疫苗接种策略,使该高危人群获得更高的血清保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with HIV (PLWH) have higher incidence of pneumococcal disease compared to people without HIV. Immunization with pneumococcal vaccines is recommended, but serological non-response to pneumococcal vaccination is common for largely unknown reasons. METHODS: PLWH on antiretroviral treatment and no prior pneumococcal vaccination received the 13-valent pneumococcal conjugate vaccine (PCV13) followed 60 days later by the 23-valent polysaccharide vaccine (PPV23). Serological response was evaluated 30 days post-PPV23 by antibodies against 12 serotypes covered by both PCV13 and PPV23. Seroprotection was defined as a ≥2-fold rise to a level above 1.3 µg/ml in geometric mean concentration (GMC) across all serotypes. Associations with non-responsiveness were evaluated by logistic regression. RESULTS: Fifty-two virologically suppressed PLWH (median age of 50 years (IQR 44-55) and median CD4 count of 634 cells/mm3 (IQR 507-792)) were included. Forty-six percent (95 % CI 32-61, n = 24) achieved seroprotection. Serotypes 14, 18C and 19F had the highest, and serotypes 3, 4 and 6B the lowest GMCs. Pre-vaccination GMC levels less than 100 ng/ml were associated with increased odds of non-responsiveness compared to levels above 100 ng/ml (adjusted OR 8.7, 95 % CI 1.2-63.6, p = 0.0438). CONCLUSION: Less than half of our study population achieved anti-pneumococcal seroprotective levels following PCV13 and PPV23 immunization. Low pre-vaccination GMC levels were associated with non-response. Further research is required to optimize vaccination strategies that achieve higher seroprotection in this high-risk group.
引用
- Tinggaard M, Slotved HC, Jørgensen CS, et al. Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV. Vaccine. 2023. PMID: 37316406. doi:10.1016/j.vaccine.2023.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。